Cargando…

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

PURPOSE: Sorafenib, a multikinase inhibitor of Raf and several growth factor receptors, is under investigation in combination with dacarbazine, a commonly used chemotherapeutic agent for the treatment of many cancers. The current phase I study investigates the effects of sorafenib on the pharmacokin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brendel, Erich, Ludwig, Matthias, Lathia, Chetan, Robert, Caroline, Ropert, Stanislas, Soria, Jean-Charles, Armand, Jean-Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123694/ https://www.ncbi.nlm.nih.gov/pubmed/20821331 http://dx.doi.org/10.1007/s00280-010-1423-9

Ejemplares similares

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

Phase I study of pemetrexed with sorafenib in advanced solid tumors
por: Poklepovic, Andrew, et al.
Publicado: (2016)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
por: Halperin, Daniel M, et al.
Publicado: (2014)

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
por: Khan, O A, et al.
Publicado: (2011)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
por: Tawbi, H A, et al.
Publicado: (2011)

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013)

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
por: Coriat, Romain, et al.
Publicado: (2011)

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
por: Tsai, Hui-Jen, et al.
Publicado: (2021)

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study
por: Coriat, Romain, et al.
Publicado: (2016)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
por: Reed, Damon R., et al.
Publicado: (2015)

A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850
por: Spencer, Kristen R., et al.
Publicado: (2023)

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
por: Lebbé, Celeste, et al.
Publicado: (2020)

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
por: Couronne, Thomas, et al.
Publicado: (2020)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles
por: Zhang, Hong, et al.
Publicado: (2012)

Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors
por: Kao, Chien-Chang, et al.
Publicado: (2022)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
por: Awada, A, et al.
Publicado: (2005)

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
por: Blay, Jean-Yves, et al.
Publicado: (2019)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Dacarbazine-encapsulated solid lipid nanoparticles for skin cancer: physical characterization, stability, in-vivo activity, histopathology, and immunohistochemistry
por: Bhattacharya, Sankha, et al.
Publicado: (2023)

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
por: Lee, Keun‐Wook, et al.
Publicado: (2017)

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer
por: Okamoto, Isamu, et al.
Publicado: (2009)

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
por: Okusaka, Takuji, et al.
Publicado: (2023)

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Dacarbazine mediates antimelanoma effects via NK cells
por: Hervieu, Alice, et al.
Publicado: (2013)

Evaluation of protective effect of amifostine on dacarbazine induced genotoxicity
por: Etebari, M., et al.
Publicado: (2015)

Dacarbazine nanoparticle topical delivery system for the treatment of melanoma
por: Hafeez, Abdul, et al.
Publicado: (2017)

Dacarbazine/doxorubicin/vinblastine: Lack of efficacy: case report
Publicado: (2022)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1sjfs0it13cog4qosqlge67jco